# A Study in Participants With Advanced Solid Tumors

> **NCT01682135** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 28 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT01682135
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682135, "A Study in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01682135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*